Sequent Scientific Valuation

Is 512529 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 512529 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 512529's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 512529's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 512529?

Key metric: As 512529 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 512529. This is calculated by dividing 512529's market cap by their current revenue.
What is 512529's PS Ratio?
PS Ratio	3.3x
Sales	₹14.54b
Market Cap	₹48.66b

512529 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.7x
Enterprise Value/EBITDA	35.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 512529's PS Ratio compare to its peers?

The above table shows the PS ratio for 512529 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.5x
JSLL Jeena Sikho Lifecare	12.5x	n/a	₹47.7b
524735 Hikal	2.7x	13.2%	₹48.4b
509079 Gufic Biosciences	5.3x	n/a	₹42.2b
524348 Aarti Drugs	1.8x	13.4%	₹42.3b
512529 Sequent Scientific	3.3x	n/a	₹48.7b

Price-To-Sales vs Peers: 512529 is good value based on its Price-To-Sales Ratio (3.3x) compared to the peer average (5.5x).

Price to Sales Ratio vs Industry

How does 512529's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

14 Companies	Price / Sales	Estimated Growth	Market Cap
NECLIFE Nectar Lifesciences	0.5x	n/a	US$92.92m
539561 Remedium Lifecare	0.07x	n/a	US$29.56m
532637 Mangalam Drugs & Organics	0.5x	n/a	US$19.93m
531173 Syschem (India)	0.5x	n/a	US$18.87m

14 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 512529 is expensive based on its Price-To-Sales Ratio (3.3x) compared to the Indian Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is 512529's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

512529 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 512529's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vilin Bio Med

₹313.9m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹22.50

-4.9%

2.3%

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹130.88

9.2%

22.1%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹926.75

-2.4%

18.8%